Login to Your Account



$2.8B Contract at Stake

PharmAthene Wins 50% of Profits; SIGA Plans Appeal

By Trista Morrison


Friday, September 23, 2011
PharmAthene Inc. scored a stunning victory in its five-year legal battle against SIGA Technologies Inc., with the Delaware Court of Chancery awarding PharmAthene half of the net profits from SIGA's smallpox drug ST-246, subject of a government contract worth up to $2.8 billion.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription